60 Iron chelation studies published in just 2014.
Don't conflate CHELATING EXCESS IRON into chelating all iron.
Zn/Ga-DFO iron-chelating complex attenuates the inflammatory process in a mouse model of asthma. http://www.ncbi.nlm.nih.gov/pubmed/25009783
Ambient air pollutants on longitudinal changes in exhaled nitric oxide (FeNO), a potentially useful biomarker of eosinophilic airway inflammation, http://www.ncbi.nlm.nih.gov/pubmed/24696513
The concentration of iron in real-world geogenic PM₁₀ is associated with increased inflammation and deficits in lung function in mice. http://www.ncbi.nlm.nih.gov/pubmed/24587402
Iron Chelators Increase IKBα Expression, Modulate CDK2 and CDK9 activities and Inhibit HIV-1 Transcription. http://www.ncbi.nlm.nih.gov/pubmed/25155598
Pediatric cancer patients, and report our experience with Iron Chelation Therapy (ICT). http://www.ncbi.nlm.nih.gov/pubmed/25154390
The iron chelator, DFX, can decrease the concentrations of iron and ferritin after cerebral hemorrhage and can thereby decrease the incidence of hydrocephalus. In addition, after IVH, the gene expression of Wnt1 and Wnt3a was enhanced, with protein expression also upregulated; DFX was able to suppress both gene and protein expression of Wnt1 and Wnt3a in brain tissue. http://www.ncbi.nlm.nih.gov/pubmed/25152462
Our results show that more than 50% of children with SCD have inadequate control of iron overload with DFX. http://www.ncbi.nlm.nih.gov/pubmed/25138173
It is concluded that iron chelation therapy can improve the efficacy of EPO to alleviate EPO resistance in patients wtih anemic MDS, decrease the pathological level of EPO, enhance Hb levels and reduce the dependency on blood transfusion. http://www.ncbi.nlm.nih.gov/pubmed/25130822
There are current clinical trials of minimally invasive hematoma removal and iron chelation which may limit such dysfunction. Understanding the mechanisms underlying the initial hemorrhage and secondary BBB dysfunction in ICH is vital for developing methods to prevent and treat this devastating form of stroke. http://www.ncbi.nlm.nih.gov/pubmed/25120903
Iron scavengers (chelators) offer therapeutic opportunities in anticancer drug design by targeting the increased demand for iron in cancer cells as compared to normal cells. http://www.ncbi.nlm.nih.gov/pubmed/25100578
Pulmonary hypertension associated with hemolytic disorders was moved from WHO group I to group V PH diseases. Treatment strategies are also unique and include blood transfusion, iron chelation, http://www.ncbi.nlm.nih.gov/pubmed/25077000
Treatment of iron overload requires robust estimates of total-body iron burden and its response to iron chelation therapy. Compliance with chelation therapy varies considerably among patients, and individual reporting is notoriously unreliable. http://www.ncbi.nlm.nih.gov/pubmed/25064711
gaba chelates iron http://www.ncbi.nlm.nih.gov/pubmed/1755517
Potentially, diets rich in polyphenols might be beneficial for patients groups at risk of iron loading by limiting the rate of intestinal iron absorption. http://www.ncbi.nlm.nih.gov/pubmed/25058155
Our data show that TPEN induces cell death by chelating copper to produce TPEN-copper complexes that engage in redox cycling to selectively eliminate colon cancer cells. http://www.ncbi.nlm.nih.gov/pubmed/25047035
Chlamydia trachomatis (Ct) is a bacterial human pathogen responsible for the development of trachoma, the worldwide infection leading to blindness, and is also a major cause of sexually transmitted diseases. As iron is an essential metabolite for this bacterium, iron depletion presents a promising strategy to limit Ct proliferation. http://www.ncbi.nlm.nih.gov/pubmed/25027937
We previously showed that ceruloplasmin knockout (CP KO) mice exhibit Parkinsonian neurodegeneration (~30% nigral loss) by 6 months, which is prevented by iron chelation. http://www.ncbi.nlm.nih.gov/pubmed/25011704 Zn/Ga-DFO
Iron-chelating complex attenuates the inflammatory process in a mouse model of asthma. http://www.ncbi.nlm.nih.gov/pubmed/25009783
Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer. http://www.ncbi.nlm.nih.gov/pubmed/25005181
Iron chelators induce autophagic cell death in multiple myeloma cells. http://www.ncbi.nlm.nih.gov/pubmed/24998390
Iron-enhanced coagulation is attenuated by chelation A thrombelastographic and ultrastructural analysis. http://www.ncbi.nlm.nih.gov/pubmed/24991945
We hypothesized that the robust immune response to Ent and Lcn2 requires iron chelation rather than the Ent+Lcn2 complex itself and also can be stimulated by Lcn2-evasive siderophores. http://www.ncbi.nlm.nih.gov/pubmed/24980968
Antioxidant properties investigated included scavenging of free radicals, iron chelation and the inhibition of lipid peroxidation http://www.ncbi.nlm.nih.gov/pubmed/24976244
Iron in excess impaired differentiation, but this antiadipogenic effect was less pronounced than under iron chelation. Of interest, expression of several genes involved in mitochondrial biogenesis occurred in parallel with expression of iron-related genes both during adipogenesis and in human adipose tissue. http://www.ncbi.nlm.nih.gov/pubmed/24973963
To investigate the retinal-protective effects of the oral iron chelator deferiprone (DFP) in mice lacking the iron regulatory hormone hepcidin (Hepc). http://www.ncbi.nlm.nih.gov/pubmed/24970260
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis. http://www.ncbi.nlm.nih.gov/pubmed/24959339
Although there is currently not enough evidence to support clinical use of iron chelation in MS, an overview of studies of iron chelation or antioxidant therapies will be also provided. http://www.ncbi.nlm.nih.gov/pubmed/24929968
Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease. http://www.ncbi.nlm.nih.gov/pubmed/24928620
Benzylidene acylhydrazides inhibit chlamydial growth in a type III secretion- and iron chelation-independent manner. http://www.ncbi.nlm.nih.gov/pubmed/24914180
Iron sensing. Part 2. Experimental detection of free iron concentration (pFe) in urine samples. http://www.ncbi.nlm.nih.gov/pubmed/24883429
Major preclinical and clinical trials have shown advances in iron-chelation therapy for the treatment of iron-overload disease as well as cardiovascular and chronic inflammatory diseases. http://www.ncbi.nlm.nih.gov/pubmed/24888568
We found that AT101 caused caspase-independent, non-apoptotic MPNST cell( malignant peripheral nerve sheath tumor cells) death, which was accompanied by autophagy and was mediated through HIF-1α induced expression of the atypical BH3-only protein BNIP3. These effects were mediated by intracellular iron chelation, a previously unreported mechanism of AT101 cytotoxicity. http://www.ncbi.nlm.nih.gov/pubmed/24824755
We found rHuEPO to be a potent scavenger of HO˙ (kr = 1.03-1.66 × 1011 m-1 s-1 ) with the capacity to inhibit Fenton chemistry through catalytic iron chelation. http://www.ncbi.nlm.nih.gov/pubmed/24811856
Patients presenting with resectable or advanced OAC could be considered as candidates for a clinical trial of iron chelation therapy as an addition to standard neoadjuvant or palliative treatments. http://www.ncbi.nlm.nih.gov/pubmed/24780018
Effective iron chelators are now available, including preparations that can be taken orally. This has resulted in substantial improvement in mortality and morbidity for patients with severe chronic iron overload. http://www.ncbi.nlm.nih.gov/pubmed/24726864
A few studies have shown that iron and proteins related to iron metabolism are closely related to HILI, and iron chelation may exert protective effects on HILI. http://www.ncbi.nlm.nih.gov/pubmed/24649714
Currently, the goal of iron chelation has shifted from treating iron overload to preventing iron accumulation and iron-induced end-organ complications, http://www.ncbi.nlm.nih.gov/pubmed/24646011
Early chelation of blood-derived iron and antioxidant treatment mitigated early motor-neuronal injury. Our data suggest that BSCB breakdown contributes to early motor-neuron degeneration in ALS mice and that restoring BSCB integrity during an early disease phase retards the disease process. http://www.ncbi.nlm.nih.gov/pubmed/24591593
Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction. http://www.ncbi.nlm.nih.gov/pubmed/24586712
Diethylenetriaminepentaacetic acid-D-deoxy-glucosamine (DTPA-DG) was synthesized and examined for its activity as a cell-permeable iron chelator in human hepatocellular carcinoma (HEPG2) cell line exposed to high concentration of iron sulfate and compared with deferoxamine (DFO), a prototype iron chelator. http://www.ncbi.nlm.nih.gov/pubmed/24554907
Cur(Que)min: a neuroactive permutation of curcumin and quercetin for treating spinal cord injury. http://www.ncbi.nlm.nih.gov/pubmed/24524922
Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure. http://www.ncbi.nlm.nih.gov/pubmed/24509160
The last decade has ushered in a new era in iron chelation therapy. Coupled with advances in tissue iron quantitation, there is tremendous promise of an individually tailored approach to chelation, and subsequent reduction in morbidity and mortality. http://www.ncbi.nlm.nih.gov/pubmed/24504090
Therapeutic phlebotomy and iron chelation are the cornerstones of therapy. The average survival is less than a year in untreated patients with severe cardiac impairment. However, if treated early and aggressively, the survival rate approaches that of the regular heart failure population. http://www.ncbi.nlm.nih.gov/pubmed/24503941
Iron homeostasis in breast cancer. http://www.ncbi.nlm.nih.gov/pubmed/24486738
R2 and R2* are equally effective in evaluating chronic response to iron chelation. http://www.ncbi.nlm.nih.gov/pubmed/24452753
Iron chelation and multiple sclerosis. http://www.ncbi.nlm.nih.gov/pubmed/24397846
Measuring LPI before starting conditioning can offer an opportunity to predict toxicity and, perhaps, the need for chelation therapy. http://www.ncbi.nlm.nih.gov/pubmed/24335268
Iron chelation is a promising, novel adjunctive therapeutic strategy for MRSA and VISA infections. http://www.ncbi.nlm.nih.gov/pubmed/24292099
Furthermore, we have demonstrated that synthetic iron chelators and a genetic iron chelator are neuroprotective against proteasome inhibitor-induced DA neuron degeneration, suggesting that iron chelation might be a promising therapeutic target for PD. http://www.ncbi.nlm.nih.gov/pubmed/24262171
Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis. http://www.ncbi.nlm.nih.gov/pubmed/24257681
Targeting chelatable iron as a therapeutic modality in Parkinson's disease. http://www.ncbi.nlm.nih.gov/pubmed/24251381
In this study, we have assessed whether high-affinity iron chelators of the pyridoxal isonicotinoyl hydrazone (PIH) class can restrict the growth of clinically significant mycobacteria. http://www.ncbi.nlm.nih.gov/pubmed/24243647
The effect of iron loading and iron chelation on the innate immune response and subclinical organ injury during human endotoxemia: a randomized trial. http://www.ncbi.nlm.nih.gov/pubmed/24241495
Pharmacological handling of monocyte migration into the CNS combined with chelators that neutralize the effects of extracellular iron occurring due to the release from dying macrophages as well as intraneuronal chelation may denote good possibilities for reducing the deleterious consequences of iron deposition in the CNS. http://www.ncbi.nlm.nih.gov/pubmed/24218010
Thanks BeauBo,
I hit the post button to quickly.
You must have spent some as a marriage counselor. I think I was too gentle with my commentary.
Did you ever read any of them? Or are you just listing them because they mention Iron and perhaps chelation? I sampled some of them, and it's obvious they are not about what you claim they are about.
These articles ALL have to do with Iron or Chelation in reference to PATHOLOGY of existing disease and how iron chelation, or the use of iron in the treatment by a drug therapy, of an existing DISEASE which was generally not in any way associated or caused by diet!
None of the diseases in these articles was in any way caused by an excess amount of iron. Some referenced injuries treatments. In fact, most of the articles had to do with how iron might have an effect on treating the disease, either by removal or by adding iron. Sometimes chelation was proper because of INJURY where blood had been released from its intended channels, such as in hemorrhages. Or how damaged cells of sickle cell disease or in Cancer patients might be affected by Chelation. These are all pathological studies and have NOTHING AT ALL TO DO WITH DIETARY IRON! ZIP! NOTHING.
This is what you get when you have people who have no idea what they are talking about pushing QUACK ideas to the ignorant public. . . Listing real scientific studies and confabulating these studies to claim they back the quackery is wrong. . . and reprehensible. Just because they happen to mention the terms the quacks choose to use, does not mean they back your position. They simply do not, by any stretch of someone's warped imagination.
We've seen it in the silver craze where people starting turning blue because they were told they needed silver in their diets, and they started taking thousands of milligrams of silver in every form they could get their hands on. We saw it in the Mercury amalgam idiocy . . . where people had perfectly good amalgam fillings removed because idiots told them they were leaching mercury into their systems from the fillings, yet the mechanical grinding of the amalgam removal resulted in their receiving far more mercury than leaving them in situ ever would. First Coffee is bad, then good, then bad, now they say five cups a day is best. Environmentally, we saw it in fear causing perfectly safe forms of asbestos being mechanically removed and reduced to dangerous aerosol dust by that removal because of irrationality. BAH!
As I told you before, when I see someone making a completely absurd claim that "The fossil record indicates humans began shrinking their brains 30k years ago" and you connect that to iron in the diet, I know that a snow job is being perpetrated. . . because I know there is no such "brain" record, anywhere. (I am pretty sure what you are hinting at, but it is unrelated to iron in the cellular structure that anyone can show or even postulate!) That means that everything else that follows is of the same level of accuracy and causality. . . and believability.
You sealed it with this list of articles.